Endotoxin (LPS)

What endotoxin actually is

Endotoxin and lipopolysaccharide are two names for the same thing. "Endotoxin" is the old physiological term — coined by Richard Pfeiffer in the 1890s to describe a toxic activity that stayed bound to the cholera bacterium rather than being secreted (an exotoxin). "LPS" is the chemical name for the molecule responsible. It lives exclusively in the outer leaflet of the outer membrane of gram-negative bacteria — organisms such as Escherichia coli, Klebsiella, Pseudomonas aeruginosa, Neisseria meningitidis, and Salmonella. Gram-positive bacteria, which lack an outer membrane, have no LPS; their inflammatory triggers are different molecules (lipoteichoic acid and peptidoglycan, sensed by TLR2).

An LPS molecule has three parts, working inward from the toxic anchor to the part that pokes out into the world:

• Lipid A — the business end. A diglucosamine backbone, usually bearing two phosphate groups and six fatty-acyl chains, that embeds LPS in the membrane. Lipid A is the toxic principle: purified lipid A reproduces the full endotoxic activity of intact LPS. The number and length of acyl chains tune potency — the canonical hexa-acylated lipid A of E. coli is the strongest agonist, while the four-chain lipid A of some other species is far weaker.
• Core oligosaccharide — a short, fairly conserved sugar chain (including the unusual sugar KDO) bridging lipid A to the outer chain.
• O-antigen — a long, repeating polysaccharide that varies enormously between strains and gives rise to the O serotypes used to name organisms (the O157 in E. coli O157:H7). The O-antigen faces outward, resists complement, and is the bacterium's coat against the host. It is not the toxic part.

From shed molecule to TLR4: the recognition cascade

The remarkable thing about endotoxin is that the toxicity is almost entirely the host's doing. LPS itself does not chew up tissue. It is a flag, and the immune system's reaction to that flag is what makes you sick. The recognition pathway is a relay of four proteins:

1. LPS-binding protein (LBP), an acute-phase plasma protein, plucks individual LPS monomers out of bacterial membranes or aggregates and acts as a shuttle.
2. CD14, present both anchored to the surface of monocytes and macrophages and floating free in plasma, receives LPS from LBP and concentrates it.
3. MD-2, a small protein, is the actual lipid A sensor. Its hydrophobic pocket swallows five of the six acyl chains of lipid A; the sixth chain and the phosphates protrude.
4. TLR4 (Toll-like receptor 4) carries MD-2 on its outside. When the exposed sixth acyl chain and the negatively charged phosphates of one loaded MD-2 contact a second TLR4/MD-2 unit, the two receptors dimerize.

That dimerization is the switch. Bringing two TLR4 tails together on the inside of the cell juxtaposes their TIR signaling domains, which then recruit adaptor proteins along two arms:

• The MyD88-dependent arm (from the plasma membrane) rapidly activates the transcription factor NF-κB, switching on genes for the early pro-inflammatory cytokines TNF-α, IL-1β, and IL-6.
• The TRIF-dependent arm (after the receptor is endocytosed) activates IRF3 and drives type I interferon production.

Within an hour, an activated macrophage is pouring out TNF-α; the febrile and hypotensive effects of LPS injection can be reproduced almost entirely by infusing TNF-α alone, which is why TNF-α was originally named "cachectin." IL-1 and IL-6 act on the hypothalamus to raise the thermal set-point — the molecular basis of fever — and IL-6 drives the liver's acute-phase response (C-reactive protein, fibrinogen, hepcidin). Inducible nitric oxide synthase floods vessels with nitric oxide, relaxing smooth muscle and dropping systemic vascular resistance.

How endotoxin becomes septic shock

In a contained infection — a urinary tract infection, a localized abscess — this cascade is exactly what you want: recruit neutrophils, raise local temperature, mark the area for the adaptive immune system, and wall off the bug. The trouble begins when the bacterial load is high and LPS reaches the bloodstream in quantity, a state called endotoxemia. Now the same response runs system-wide:

• Vasodilation and distributive shock. Nitric oxide and other mediators relax arterioles everywhere at once. Systemic vascular resistance collapses, and blood pressure falls despite a normal or high cardiac output — "warm shock." Eventually the heart is depressed too (a poorly understood myocardial depressant effect of sepsis), and the patient decompensates.
• Capillary leak. Endothelial junctions loosen, so fluid and protein flood into the interstitium. Patients become profoundly edematous even as the intravascular space empties, demanding liters of resuscitation fluid.
• Disseminated intravascular coagulation (DIC). LPS, via TLR4 on endothelium and monocytes, switches on tissue factor, igniting the coagulation cascade throughout the microvasculature. Tiny clots consume platelets and clotting factors, so the patient simultaneously thromboses small vessels and bleeds from puncture sites. In meningococcemia this produces the catastrophic skin hemorrhages and adrenal infarction of Waterhouse-Friderichsen syndrome.
• Organ failure. Microvascular clotting, hypotension, and direct cytokine injury starve the kidneys, lungs (acute respiratory distress syndrome), and liver of oxygen, producing the multi-organ dysfunction that kills.

Quantitatively, the dose-response is steep and fast. A few nanograms of LPS per kilogram given intravenously produce fever and a TNF-α spike in healthy volunteers within one to two hours. The numbers that matter clinically are not absolute LPS concentrations — which are hard to measure reliably — but the downstream signs codified in the Sepsis-3 definitions: a rise of two or more points on the SOFA organ-dysfunction score for sepsis, and, for septic shock, the need for vasopressors to keep mean arterial pressure at or above 65 mmHg together with a serum lactate above 2 mmol/L. Septic shock so defined carries hospital mortality above 40%.

Endotoxin versus exotoxin: a clean contrast

Students perennially blur endotoxins and exotoxins. The distinction is real and clinically useful — they differ in chemistry, source, potency, and how medicine fights them.

Feature	Endotoxin (LPS)	Exotoxin
Chemical nature	Lipopolysaccharide (glycolipid)	Protein
Source organisms	Gram-negative bacteria only	Gram-positive and gram-negative
Location / release	Outer membrane; shed on division, lysis, or killing	Actively secreted by living bacteria
Host sensor / target	TLR4/MD-2 on immune and endothelial cells	Specific cell receptors and enzymes
Effect	Broad, stereotyped: fever, shock, DIC	Disease-specific (paralysis, diarrhea, etc.)
Potency	High but graded; needs many molecules	Often extreme (botulinum is the most potent toxin known)
Heat stability	Very stable (to 250°C)	Usually heat-labile
Convertible to toxoid vaccine?	No	Yes (tetanus, diphtheria toxoids)
Examples / diseases	Meningococcemia, gram-negative sepsis	Cholera, tetanus, botulism, diphtheria

Where endotoxin shows up in real medicine

• Gram-negative sepsis. The prototype. Bloodstream infection with E. coli, Klebsiella, or Pseudomonas floods the circulation with LPS and drives the septic cascade.
• Meningococcal disease. Neisseria meningitidis sheds enormous quantities of LPS in outer-membrane blebs; blood endotoxin levels in fulminant meningococcemia are the highest measured in any human infection and correlate with mortality and the rapidity of purpuric collapse.
• Pharmaceutical safety. Because LPS is heat-stable and pyrogenic at nanogram doses, every injectable drug, IV fluid, vaccine, and implanted device must be proven endotoxin-free. The Limulus amebocyte lysate (LAL) assay — exploiting the clotting reaction of horseshoe-crab blood cells to LPS — is the standard test, with limits typically below 0.5 endotoxin units per milliliter. "Sterile" is not enough: a solution can be free of living bacteria yet still loaded with endotoxin from dead ones.
• The leaky gut and metabolic disease. The gut lumen holds vast amounts of LPS from resident gram-negative flora. Low-grade translocation of LPS across a compromised intestinal barrier ("metabolic endotoxemia") is implicated in the chronic low-grade inflammation of obesity, fatty liver disease, and insulin resistance.
• The Shwartzman reaction and tolerance. A first sublethal dose of LPS can prime tissues so a second dose triggers hemorrhagic necrosis (the local Shwartzman reaction) — yet at the cellular level, prior LPS exposure usually induces tolerance, blunting later responses, a key driver of the immunosuppressed late phase of sepsis.

Why blocking endotoxin rarely works

For forty years the obvious therapeutic idea has been to neutralize endotoxin or block TLR4. Anti-lipid-A antibodies (HA-1A, E5), the synthetic TLR4 antagonist eritoran, and polymyxin-B endotoxin-adsorbing hemoperfusion columns have all been tested in large sepsis trials. Almost none improved survival. The lessons are worth stating plainly: by the time a patient is in shock, the cytokine network downstream of TLR4 is self-amplifying and no longer needs LPS; a large share of sepsis is not gram-negative at all; and removing one trigger or one mediator from a redundant, dysregulated host response changes little. This is why modern sepsis care is built on speed and fundamentals — early broad-spectrum antibiotics, source control, fluid resuscitation, and vasopressors titrated to a mean arterial pressure of 65 mmHg — rather than on a magic anti-endotoxin bullet.

This article is educational and not medical advice. Sepsis is a medical emergency; if you suspect it, seek care immediately and rely on a qualified clinician for diagnosis and treatment.